Table 3.
Association between the lipid genotype scores and risk for preeclampsia, preeclampsia replication population
| Continuous | Quartile | P for trend | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| Total cholesterol | ||||||
| n (case/control subjects) | 136/267 | 133/270 | 122/280 | 125/280 | ||
| Median (range) | 29.5 (20.4–31.2) | 32.5 (31.2–33.6) | 34.6 (33.6–35.9) | 37.6 (35.9–43.5) | ||
| OR (95% CI) | ||||||
| PCA adjusted | 0.98 (0.95, 1.01) | 1.00 (Ref) | 1.01 (0.74, 1.38) | 0.91 (0.67, 1.25) | 0.85 (0.63, 1.16) | 0.26 |
| LDL cholesterol | ||||||
| n (case/control subjects) | 130/273 | 140/263 | 131/272 | 115/289 | ||
| Median (range) | 15.8 (7.5–17.5) | 18.8 (17.5–19.9) | 21.0 (19.9–22.4) | 23.9 (22.4–29.4) | ||
| OR (95% CI) | ||||||
| PCA adjusted | 0.98 (0.95, 1.02) | 1.00 (Ref) | 1.02 (0.75, 1.40) | 1.07 (0.78, 1.46) | 0.81 (0.59, 1.10) | 0.16 |
| HDL cholesterol | ||||||
| n (case/control subjects) | 125/278 | 122/281 | 127/276 | 142/262 | ||
| Median (range) | 19.4 (10.7–21.8) | 23.2 (21.8–24.6) | 25.9 (24.6–27.1) | 28.7 (27.2–34.0) | ||
| OR (95% CI) | ||||||
| PCA adjusted | 1.03 (1.00, 1.06) | 1.00 (Ref) | 0.98 (0.72, 1.35) | 1.06 (0.77, 1.46) | 1.31 (0.95, 1.81) | 0.12 |
| Triglycerides | ||||||
| n (case/control subjects) | 133/270 | 133/270 | 113/290 | 137/267 | ||
| Median (range) | 18.0 (11.0–19.2) | 20.1 (19.2–21.0) | 21.8 (21.0–22.8) | 24.0 (22.8–29.6) | ||
| OR (95% CI) | ||||||
| PCA adjusted | 1.00 (0.96, 1.05) | 1.00 (Ref) | 1.00 (0.73, 1.36) | 0.76 (0.55, 1.05) | 1.00 (0.73, 1.37) | 0.84 |
P value for test for trend from Cochrane–Armitage test for trend. Abbreviations: CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio; PCA, principal components analysis for population stratification.